Investigating the role of SOX11 in aggressive B-cell lymphoma
Official title: Targeting SOX11 in Mantle Cell Lymphoma
Funded at Icahn School of Medicine at Mount Sinai · NIH-10854812 · Data updated 2026-11-12
This study is looking at how a protein called SOX11 affects the growth of Mantle Cell Lymphoma, a serious type of blood cancer, using special mouse models to help find new ways to treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2020 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $534,024 |
| NIH project number | 5R01CA252222-05 |
| Project ID | NIH-10854812 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Mantle Cell Lymphoma or those at risk for developing this aggressive form of cancer.
✕Less likely to help
Patients with other types of Non-Hodgkin's Lymphoma or those without a diagnosis of B-cell malignancies may not benefit from this research.
What this research studies
This research focuses on understanding how the SOX11 transcription factor contributes to the development and progression of Mantle Cell Lymphoma (MCL), a severe form of B-cell Non-Hodgkin's Lymphoma. By utilizing specially developed mouse models that mimic human MCL, the researchers aim to explore the interactions between SOX11 and other genetic factors like Cyclin D1. The study will involve analyzing the behavior of B cells in these models to uncover mechanisms that drive the disease. Patients may benefit from insights gained that could lead to new treatment strategies targeting SOX11.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that specifically target SOX11, improving outcomes for patients with Mantle Cell Lymphoma.
How similar studies have gone: Previous research has shown promising results in targeting genetic factors in lymphoma, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Parekh, Samir — Icahn School of Medicine at Mount Sinai
- Study coordinator: Parekh, Samir
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.